Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B lymphocytes. Despite great progress recently achieved in the management of CLL, the disease remains incurable, underscoring the need for further investigation into the underlying pathophysiology. Microenvironmental crosstalk has an established role in CLL pathogenesis and progression. Indeed, the malignant CLL cells are strongly dependent on interactions with other immune and non-immune cell populations that shape a highly orchestrated network, the tumor microenvironment (TME). The composition of the TME, as well as the bidirectional interactions between the malignant clone and the microenvironmental elements have been linked to disease heterogeneity. Mounting evidence implicates T cells present in the TME in the natural history of the CLL as well as in the establishment of certain CLL hallmarks e.g. tumor evasion and immune suppression. CLL is characterized by restrictions in the T cell receptor gene repertoire, T cell oligoclonal expansions, as well as shared T cell receptor clonotypes amongst patients, strongly alluding to selection by restricted antigenic elements of as yet undisclosed identity. Further, the T cells in CLL exhibit a distinctive phenotype with features of “exhaustion” likely as a result of chronic antigenic stimulation. This might be relevant to the fact that, despite increased numbers of oligoclonal T cells in the periphery, these cells are incapable of mounting effective anti-tumor immune responses, a feature perhaps also linked with the elevated numbers of T regulatory subpopulations. Alterations of T cell gene expression profile are associated with defects in both the cytoskeleton and immune synapse formation, and are generally induced by direct contact with the malignant clone. That said, these abnormalities appear to be reversible, which is why therapies targeting the T cell compartment represent a reasonable therapeutic option in CLL. Indeed, novel strategies, including CAR T cell immunotherapy, immune checkpoint blockade and immunomodulation, have come to the spotlight in an attempt to restore the functionality of T cells and enhance targeted cytotoxic activity against the malignant clone.

Keywords: chronic lymphocytic leukemia, T lymphocytes, anti-tumor immunity, tumor microenvironment, T cell-based therapies
INTRODUCTION

Chronic lymphocytic leukemia (CLL) is an age-related malignancy characterized by the accumulation of monoclonal mature B cells expressing CD5, CD19 and CD23 on their surface (1). Numerous studies support that the clonotypic B cell receptor immunoglobulin (BcR IG) is critically implicated in disease pathophysiology (2). Indeed, the intensity of intracellular signaling downstream of the BcR in CLL cells is associated with cell proliferation and disease severity (3), whereas restrictions in the gene repertoire of the clonotypic BcR IG strongly highlight the role of antigenic triggering in disease pathogenesis (4, 5).

Different lines of evidence suggest that interactions with two main categories of microenvironmental components i.e. soluble factors and other extracellular elements as well as bystander cells are implicated in shaping a supportive tumor microenvironment (TME) in CLL (6–8). The former category includes various extracellular molecules (e.g.) cytokines, chemokines, antigens but also, in a broader sense, products of metabolic processes. Indeed, although cellular metabolism in CLL remains largely unexplored, increasing evidence implicates oxidative stress in the natural history of CLL by showing e.g. that the accumulation of reactive oxygen species (ROS) may hold prognostic significance (9, 10).

Turning to bystander cells, different subpopulations of T cells as well as natural killer (NK) cells accumulate in vivo along with mesenchymal stromal cells (MSC) and nurse-like cells (NLCs), forming a complex network that favors clonal expansion and proliferation of the malignant clone (11–13). Ongoing crosstalk of CLL malignant cells with these other cell populations in the TME affects the function of both parties. On the one hand, this leads to immunosuppression, a hallmark of CLL associated with increased susceptibility to infections, autoimmune manifestations, and a higher incidence of secondary malignancies (14). On the other hand, external triggers support the survival and proliferation of the neoplastic cells (15); this was first made evident when it was found that CLL cells undergo apoptosis in suspension cultures, which can be partially rescued by co-cultures with stromal cells or NLC (11).

T cells are major contributors to adaptive immunity, actively engaged in defense against pathogens and tumor cells through a great variety of accessory and effector functions. Upon encounter with a specific antigen, T cells are activated and eventually differentiate into various distinct subpopulations, acquiring either cytotoxic or helper properties. Pathogen clearance, mediated by cytotoxic T cells or through the activation of other cell types induced by cytokines secreted from T helper cells, is followed by the apoptosis of the effector T cells as a homeostatic mechanism that restores the immune system at the pre-activation state. Simultaneously, a small fraction of antigen-specific memory T cells are resting in the body, ready to generate an immediate and effective secondary response (16, 17). This homeostatic balance is perturbed in CLL, where, similar to various solid or hematological malignancies, T cells exhibit a number of phenotypic and functional defects undermining their normal immune responses (18). Moreover, T cells appear to have an active involvement in CLL development and evolution, as supported by experimental evidence that the transfer of autologous activated T cells in NOD/Shi-scid, γcnull (NSG) mice is a prerequisite for successful engraftment of CLL cells in murine models (19, 20). Interestingly, the post-transfer outgrowth of functionally competent Th1 T cells seen in NSG mice highlights the suppressive and inhibitory TME in CLL patients, particularly considering reports that these T cells can regain their functionality and promote B cell diversification and differentiation (18). It has been proposed that this phenomenon may reflect selection for Th1 cells in vivo, release from various inhibitory mechanisms operating within the human host or a special effect of the distinct NSG microenvironment. Arguably, similar mechanisms may also act in CLL patients, however, strong correlations remain elusive (20), highlighting the need for caution when attempting extrapolations based on findings deriving from model systems.

In CLL, as in other cancers, genomic instability leads to various alterations that serve as a source of cognate antigens, sufficient for the induction of tumor-reactive T cell responses (21–24). Although tumor-/antigen-specific T cells have been identified in CLL patients, these are incapable of effectively eliminating neoplastic cells due to several intertwined immunosuppressive mechanisms that establish T cell dysfunction (25, 26), thus, favoring escape from immune surveillance (27). Evidence suggests that this tolerogenic TME is actively induced by the CLL cells themselves through the secretion of cytokines and chemokines that affect cellular functions in the bystander cells (15). As a matter of fact, a recent study demonstrated that shared peptides from the highly conserved BcR IG of patients belonging to CLL stereotyped subsets 1 and 2 could generate antigen-specific T cells upon presentation in HLA-restricted manner. Furthermore, that study reported T cell specific reactivity against CLL cells, while also showing that immunization of Fl-TCL1 mice with BcR IG-derived peptides led to anti-leukemic T cell responses, implying that targeted T cell immunotherapy against the clonotypic BcR IG represents an appealing treatment option (28). Along similar lines, the identification of the unique set of neo-epitopes of each patient could lead to the isolation of leukemia-specific T cells, that can be used as a novel treatment approach (29).

Taken together, deciphering the cross-talk mechanisms between CLL cells and bystander T cells as well as the implicated signaling pathways is reasonably anticipated to offer insights into disease pathophysiology, and, potentially, a great opportunity for designing microenvironment-directed treatment approaches.

T CELL SUBPOPULATION IMBALANCES IN CLL

Alterations in the T cell composition have been extensively described in CLL, however the exact impact of these changes on disease development and progression remains controversial. The first described T cell abnormality in a CLL-specific context concerned the finding of increased numbers of T cells in the
periphery, accounting mostly for CD8⁺ T cell expansion that leads to inversion of the normal CD4⁺/CD8⁺ cell ratio (30). Of note, these CD8⁺ T cells are severely compromised as to their capacity to exert cytotoxicity (31). Regarding the potential clinical relevance of these findings, it has been reported that elevated numbers of CD8⁺ cells are associated with disease progression as well as shorter time to first treatment and progression-free survival, perhaps partly due to co-expression of the inhibitory receptor of programmed death-1 (PD-1) (32). However, under different conditions oligoclonal expansion of CD8⁺ effector cells in the Eµ-TCL1 mouse model of CLL has been associated with disease control, whereas conversely, ablation of CD4⁺ T cells did not affect disease progression (33).

Expansions of different CD4⁺ T cell subpopulations that exert either pro-tumoral activity or immunosuppression have been reported in CLL. Early studies have shown that IFN-γ secreting Th1 cells can provide trophic signal for CLL cells inhibiting programmed cell death and supporting survival (34). On the other hand, T cell-mediated immune responses have been linked with disease control in cases of autologous CLL regression, highlighting the multi-dimensional T cell activity into the CLL TME (35). Further, expansion of a novel CD4⁺ T subpopulation characterized by the expression of the TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitory receptor has been recently observed in patients at advanced stages of CLL; these cells were shown to support CLL survival in in vitro experiments (36). Finally, CD4⁺PD-1⁺HLA-DR⁺ T cells that co-express inhibitory and activation markers have been associated with aggressive disease (37). Altogether, these apparently conflicting findings clearly indicate the need for delving deeper into the distinct subsets and functions of the T cell compartment in CLL.

A well-characterized finding in CLL concerns the elevated numbers of T regulatory cells (Tregs) (30, 38) that are generally known to contribute to cancer progression through dampened antitumor responses and immunosuppression (39, 40). Of note, CLL Tregs are more suppressive than normal Tregs, whereas depletion of these cells led to efficient anti-tumor responses in animal models of CLL (41, 42). Additionally, interleukin 4 (IL-4) secreted from Tregs also induces anti-apoptotic pathways in CLL cells through the overexpression of the anti-apoptotic protein BCL2, which is therapeutically targeted by venetoclax, an effective agent for the treatment of CLL (43–46). Hence, efforts to inhibit Tregs through targeting the FoxP3 transcription factor, that is critical for their function (47, 48), or other interacting molecules in the downstream pathway could be clinically useful, at least in principle, similar to what has been proposed for other cancers (49, 50).

Th17 cells represent another T cell subpopulation with a critical role in immune homeostasis, actively participating in inflammatory processes. Imbalances in Th17 populations have been linked with autoimmune disorders, however their role in cancer remains to be fully elucidated (51). In CLL, Th17 cells are increased compared to healthy individuals; however, increased Th17 cells in cases at early disease stages have been reported to be associated with a favorable clinical outcome, conceivably through controlling the expansion of Tregs (52, 53). Altogether, the aforementioned evidence suggests that the balance between Tregs and Th17 cells may impact on the clinical outcome through as yet unknown mechanisms (14, 51).

**FUNCTIONAL IMPAIRMENT OF T CELLS IN CLL: CAUSES, FUNCTIONAL CONSEQUENCES, AND CLINICAL IMPLICATIONS**

T cell activation starts when an antigen-presenting cell (APC) introduces an epitope bound on an HLA molecule to a specific TR. A second signal from the CD28 receptor, constitutively expressed on T cells, enhances cell proliferation, generation of cytotoxic lymphocytes, and cytokine production (54). In CLL, *in vitro* T cell activation through CD28 followed by infusion of the activated autologous T cells to the patients was shown to lead to competent anti-leukemic effects and decreased TR clonality. Based on this evidence, *ex vivo* T cell activation and expansion was proposed as a valid treatment option in CLL, however failed to gain ground (55).

Effective activation of naïve T cells through normal interactions with APCs requires the formation of the immune synapse, a specialized contact area between T cells and APCs (56). Impaired immune synapse formation has been documented as a hallmark of CLL and shown to be mechanistically linked to alterations in the expression of genes associated with actin polymerization, cytoskeletal organization and vesicle trafficking (57). Of note, immune synapse defects appear to be contact-dependent, as shown in both *ex vivo* studies of primary patient samples and *in vivo* studies of animal models of CLL (58, 59).

Such effects may dampen effective antitumor responses, through a complex network of inhibitory signals and immunosuppressive interactions amongst CLL cells and T cells into TME. Importantly, signals delivered through the CTLA-4 and PD-1 receptors modulate T cell activation status through reduction of TR signaling and cytolytic functions. These inhibitory molecules are overexpressed in T cells of patients with CLL, while their ligands are also overexpressed by the malignant cells, hence putting the brakes on anti-tumor activity (60). Specifically, CLL cells express inhibitory surface molecules from B7 and TNF-Receptor families, namely CD200, CD274 (PD-L1), CD276 and CD270 which are implicated in synapse formation defects in both autologous and allogeneic T cells, suggesting a novel evasion mechanism (61).

On these grounds, research into these receptors and ligands could pave the way to novel treatment modalities for CLL, whereby T cell-driven immune responses could be re-invigorated through targeting the interactions between inhibitory receptors and their ligands. However, despite encouraging pre-clinical results, the clinical application of antibodies against these receptors (immune checkpoint inhibitors [ICI]) has been frustratingly disappointing in CLL,
with only minimal effectiveness when administered as monotherapy (62, 63). Evidently, more research is warranted in order to define the precise role of ICIs in the management of CLL and also better understand the mechanisms underlying the emergence of severe adverse events reported for these agents (64, 65).

In CLL, immune synapse defects were found to be reversible by the administration of lenalidomide, an immunomodulatory drug (IMiD) that appears to reshape the expression of cytokines and orchestrate cell-mediated responses, mobilizing the T cell compartment (66, 67). In addition, lenalidomide treatment invigorates T cell motility and migration through activation of integrin lymphocyte function–associated antigen-1 (LFA-1), also affected by direct contact with CLL cells (68). Relevant to mention, clinical studies of lenalidomide as monotherapy or consolidation therapy after chemoimmunotherapy have reported restored immune synapse formation and downstream signaling and well as improved quality of clinical responses (69, 70).

T cells in CLL display features of exhaustion, a functional state initially described in the setting of chronic infections but later also recognized in various cancer types (25, 71–75). In such conditions, exhaustion has been postulated to arise as a result of persistent antigenic stimulation, leading to gradual loss of T cell effector functions (76–78). Similar to other contexts, exhausted T cells in CLL are characterized by low proliferative rates, reduced cytotoxicity, altered cytokine production and, as already mentioned, expression of multiple inhibitory receptors on their surfaces, including CTLA-4, PD-1 and LAG-3 (25, 79, 80).

The functional analogies between T cells in individuals exposed to persistent antigenic stimulation due to a chronic infection and individuals affected by CLL allows arguing that antigenic pressure is key to shaping the T cell repertoire and functionality also in CLL. That notwithstanding, the exact nature of the cognate antigens/epitopes implicated in T cell selection in CLL is yet to be defined. However, the most prominent (classes of) candidates concern: (i) the same antigens that are implicated in the selection of the CLL progenitors or the malignant cells themselves; (ii) tumor-derived epitopes from aberrant proteins expressed by the malignant cells e.g. due to a pathogenic mutation or other genomic aberration; and (iii) the clonotypic IG, perhaps the most abundant clone-specific molecule (81–84) (Figure 1).

**ANTIGEN SELECTION SHAPES THE T CELL COMPARTMENT IN CLL: IMMUNOGENETIC EVIDENCE**

The clonotypic BcR IG is critically implicated in the natural history of CLL, a fact amply supported by the therapeutic efficacy of agents interfering with BcR IG signaling, which have changed dramatically the therapeutic landscape of CLL (85–87). This clinical evidence complements immunogenetic evidence that the BcR IG is a key driver in disease ontogeny and evolution. In more detail, the BcR IG gene repertoire is characterized by remarkable restrictions (88), culminating in BcR IG stereotypy where, at

![Figure 1](https://www.frontiersin.org/articles/10.3389/fimmu.2020.612244/full/#figure1)

**FIGURE 1** | Phenotypic and functional defects of T cells in CLL.
clear odds with serendipity, different clones share (quasi) identical IG (4, 5, 89). Moreover, the molecular characteristics of the clonotypic BcR IG have established prognostic and predictive significance since patients with a significant imprint of somatic hypermutation (SHM) display indolent disease, in contrast to those with few or no SHM who generally follow a more aggressive clinical course (90, 91). Taken together, these features emphasize the links between BcR IG structure and clonal behavior, while also highlighting the importance of antigen selection in CLL pathophysiology (92, 93).

Considering the importance of extracellular cues for CLL cell survival and proliferation, as well the T cell compartment defects in CLL patients, the interest in the TR gene repertoire of T cells in CLL and the implicated antigens is hardly surprising. Immunophenotypic studies in the 1990s described T cell clonal expansions in CLL patients, prompting speculations that these cells could be possibly related to the host immune response against CLL-derived antigens, or emerged as a result of a longitudinal interplay between CLL and T cells in the proliferative centers (94). Moreover, analyses of the TR beta (TRB) chain gene rearrangements by Southern blotting offered proliferative centers (94). Moreover, analyses of the TR beta (TRB) chain gene rearrangements by Southern blotting offered first molecular evidence for skewed TRBV gene repertoire and oligoclonality in both CD4+ and CD8+ T cells of CLL patients compared to healthy aged-matched controls (95–97). Additionally, stimulation of isolated T cells from CLL patients with autologous malignant cells resulted in monoclonal TR expansions, prompting speculations that CLL patients could bear a pool of T cells that specifically recognize leukemia-associated antigens (95, 98). Similar findings of decreased clonal diversity were also reported in Eμ-TCL1 mice supporting the notion of CLL-dependent antigen-driven selection pressure on the TR gene repertoire (99).

These initial studies were followed by significantly more extended examinations of the TR gene repertoire by our group, first through subcloning of TRBV-TRBD-TRBJ gene rearrangements followed by Sanger sequencing (100) and, more recently, by high-throughput approaches using next generation sequencing (NGS) (101, 102). Summarizing our findings: (i) the TRBV gene repertoire is skewed; (ii) oligoclonal T cell expansions feature prominently, particularly amongst cytotoxic T cells; (iii) such expansions persist and may even increase during the disease course; and, (iv) identical or highly similar TR clonotypes were shared between different patients, especially those belonging to the same stereotyped subset, and these appeared to be CLL-biased as they were not present in other contexts. Altogether, these findings allow arguing that antigen selection has a key role in shaping the TR repertoire in CLL, while also favoring the intriguing hypothesis that the relevant antigens are most likely CLL-related (101). However, the exact mechanism that underlies T cell clonality and retains these expanded populations during the disease course remains elusive.

In order to further understand T cell compartment dynamics in CLL, we extended our studies to longitudinal investigation (pre/post-treatment) of patients treated with chemoimmunotherapy with the fludarabine-cyclophosphamide-rituximab (FCR) regimen or the BcR signaling inhibitors (BcRi) ibritinib (IB) and idelalisib (the latter in combination with rituximab, R-ID).

We found that T-cell clonality significantly increased at (i) 3 months in the FCR and R-ID treatment groups, and (ii) over deepening clinical response in the R-ID group, with a similar trend detected in the IB group. Perhaps more importantly, in contrast to FCR that induced T-cell repertoire reconstitution, BcRi retained pretreatment clones. Extensive comparisons of the CLL dataset against external TR sequence databases showed little similarity with other entities, but instead revealed major TR clonotypes shared exclusively by patients with CLL, supporting selection by conserved CLL-associated antigens. In addition, we assessed the functional impact of these treatments on T cells and found that (i) R-ID upregulated the expression of activation markers in effector memory T cells, and (ii) both BcRi improved antitumor T-cell immune synapse formation, in marked contrast to FCR (102). Here, it is worth mentioning the contradictory findings of an another NGS-based longitudinal study of the TR gene repertoire in IB-treated patients, where this therapy resulted in TR repertoire diversification (103). However, major differences in the experimental and analytical procedures render these two studies incomparable, highlighting the need for further harmonization of the NGS protocols and bioinformatics workflows. A limitation inherent to both studies concerns the fact that total CD3+ T cells rather than particular T cell subpopulations were investigated, which could lead to misinterpretation due to a “dilution effect” by bulk T cell analysis. Finally, robust conclusions regarding the links, if any, between T cell dynamics overtime and clinical outcome are still not possible: hence studies on larger, well-characterized cohorts remain of paramount importance.

Considering mounting evidence that the TR gene repertoire in CLL is antigen selected, identifying the cognate antigens is an obvious line of research, not least because it would assist in designing effective antigen-specific immunotherapy. Studies of HLA-presented antigenome and computational models for tumor-associated antigen prediction proposed the existence of disease specific antigens, deriving from CLL-related genomic aberrations, that were identified exclusively on neoplastic cells of CLL patients (104–106). Additionally, the broad representation of BcR IG-derived epitopes in patients across different disease (Binet) stages and through various treatments suggest them as potential candidates for peptide vaccines and objectives of neoantigen-targeting immunotherapies. However, immune tolerance mechanisms can turn the BcR IG-derived peptides, a potentially significant pool of cognate neo-antigens in B cell lymphomas (107, 108), into ineffective targets for T cells. This phenomenon, known as immunoeediting, has been described in different contexts (including cancer and viral infections) and can neutralize an immunogenic phenotype favoring cells to survive and proliferate (27, 109).

**TREATMENT OPTIONS IN CLL AND IMPLICATION OF THE T CELL COMPARTMENT**

T cells in the CLL TME exhibit a number of phenotypic and functional defects, acquired through persistent crosstalk with the
neoplastic cells. The T cell compartment aberrations appear to be CLL-specific and induced by the CLL cells, leading to functional exhaustion, reduced activation and proliferation of effector subpopulations and decreased cytotoxic responses. Thus, CLL cells have the ability to alter T cell functions in order to evade immune-surveillance, proliferate and further expand overtime.

Despite the severe T cell deficiencies identified in CLL patients and models, studies demonstrate that subsets of these defective T cells can restore their functionality and mount anti-tumor responses under particular therapeutic interventions (Figure 2). Moreover, the identification of tumor-derived antigens implicated in T cell clonal expansions that may harbor anti-tumor properties can pave the way for therapeutic peptide vaccination strategies and adoptive T-cell transfer protocols in order to augment efficacy and guide the specificities of anticancer immune responses. Consequently, deep understanding of tumor-derived T cell dysfunction is highly significant for the development of new therapeutic modalities to restore anti-tumor immunity and result in tumor control.

In recent years, the advent of BCRi has led to a major paradigm change in the treatment of CLL. Due to structural and functional similarities of kinases between T and B cells, cross-reactivity of these agents has been described, highlighting an additional immunomodulatory mechanism of action in TME. In more detail, besides inhibiting the Bruton’s tyrosine kinase (BTK) that is implicated in signal transduction of the activated BcR in CLL cells (110), ibrutinib targets also the T-cell associated kinase ITK, modulating T cell immunity. This is made manifest by effective immune synapse formation, shift towards Th1 polarization, and expansion of functionally competent specific T clones, possibly contributing in deepening clinical response (102, 111, 112). In addition, ibrutinib-induced down-regulation of the PD-1/PD-L1 axis and inhibition of the STAT3 pathway modulates the immunosuppressive TME: on these grounds, combination protocols with lenalidomide or checkpoint inhibitors hold promises for reactivation of anti-tumor immunity (113–115). Similar effects have been demonstrated by treatment with idelalisib that also targets other PI3K isoforms in T cells, enhancing anti-tumor functions through modulation of Tregs (74). This is unsurprising considering that intracellular signaling that leads to suppression of T cell effector functions is extensively dependent on pathways implicating an isoform of PI3K that constitutes an excellent target for idelalisib. At a first glance, this effect might be considered as an alternative mechanism to reduce immunosuppression and invigorate T cell responses; however, the described severe autoimmune adverse effects cannot be overlooked (116). Effects on the CLL TME are not restricted to BCRi though, since treatment with the BCL2 inhibitor venetoclax has been associated with reduced numbers of PD-1+ T cells and expression of inflammatory cytokines, suggesting a mechanism of immune recovery (117). Collectively, thorough investigation of the possible immunomodulatory effects of novel agents in CLL is of great relevance for future development of new combination therapeutic strategies.
As already mentioned, interactions between inhibitory receptors and their ligands, including the PD-1/PD-L1 axis, enable CLL cells to evade T cell immunosurveillance, thus proposing a new area for therapeutic targeting. Preclinical studies in a murine CLL model showed that immune checkpoint inhibition of PD-1/PD-L1 led to prevention of immune dysfunction and leukemia development, hence offering a rationale for the clinical testing of these regiments (58). Despite the promising results of PD-1 blockade in clinical trials for metastatic melanoma (MM), non-small cell lung cancer (NSCLC) and renal cell cancer (RCC) (118), anti–PD-1 monotherapy benefits only a small fraction of CLL patients who developed Richter syndrome (64). Nevertheless, combination therapies with regimens targeting different inhibitory pathways may offer better outcomes (71, 119).

Adoptive T cell therapy is an evolving field that shows promises in recent trials. The protocol is based on the infusion of genetically modified T lymphocytes with a particular specificity for antigen recognition on the malignant cells. In CLL, the expression of the CD19 surface molecule is used as a selective B cell target and autologous cytotoxic T cells are modified ex vivo to express a chimeric antigen receptor (CAR) with affinity to CD19 of CLL cells. The engagement of a CAR-T cell with a CD19+ B cell leads to T cell activation in a MHC-independent manner, redirecting cytotoxic effects towards CLL cells (120). Encouraging results from adoptive T cell therapy in B acute lymphoblastic leukemia have paved the way for trials in CLL; initial results were deemed positive, but the overall efficiency of the approach was limited in patients with bulky lymph node involvement (121). Attempts to induce the anti-tumor properties and the efficiency of the CAR-T cells are based on, amongst others, modifications for constitutive expression of the CD40 ligand that lead to proliferation and Th1 immune responses, whereas also combination with PD-1 blockade has been used in order to bypass CAR-T exhaustion (121, 122).

A major challenge for effective CAR-T cell designs is to enhance and guide specificity towards the malignant cells. Thus, identification and in-depth characterization of T cell clones bearing anti-tumor properties emerge as highly relevant. In parallel, detailed studies on the HLA-lingadome highlight tumor-derived antigens that are exclusively expressed on the leukemic cells and represent possible effective targets for adoptive T cell therapy (107, 123). Additionally, the identification of anti-CLL T clones and the respective disease-specific cognate antigens offers a rationale for peptide vaccination strategies in order to induce anti-tumor responses, but also for target recognition for T-cell based immunotherapy. Indeed, spectrometric studies on the naturally presented HLA ligands in CLL identified a pool of antigens exclusively expressed in CLL patients, providing information regarding the immunogenicity of the malignant cells while also offering new treatment targets (107). However, clinical studies targeting neoepitopes expressed in the malignant cells demonstrate enhanced rejection of tumor cells, underling the safety profile of these approaches (124, 125).

**CONCLUDING REMARKS**

CLL cells have the ability to transform the effector functions of the bystander T cells in the TME, thus rendering them a source of trophic signals for the survival and proliferation of the malignant clone. Moreover, alterations in the T cell transcriptome combined with functional exhaustion undermine cytotoxic responses against tumor cells, establishing tumor evasion and escape of CLL cells from immunosurveillance. That said, despite the observed defects in the T cell compartment, several studies have identified subsets of T cells bearing anti-tumor properties that can be unleashed under the proper stimulation. This binary, contradicting role of T lymphocytes in CLL TME supports the analogy with a two-edged sword. Based on the observations discussed in the current review, the mobilization of exhausted T cells and the invigoration of anti-tumor pathways could be translated to clinical efficiency, tumor control and durable remissions. However, in order for this objective to be met, detailed characterization of the implicated mechanisms at the molecular and cellular level is urgently warranted.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the article and approved the submitted version. EV wrote the manuscript. KS and AC edited the text and gave final approval.

**FUNDING**

This work is supported in part by the ERANET Transcan-2, Project Acronym: Novel, and the Hellenic Precision Medicine Network in Oncology.

**ACKNOWLEDGMENTS**

The authors wish to acknowledge the work of past and current group members, particularly Drs Anna Vardi, Fotis Psomopoulos, Kostas Pasentis, and Niki Stavroyianni.

**REFERENCES**

1. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. *Nat Rev Dis Prim* (2017) 3:1–22. doi: 10.1038/nrdp.2016.96

2. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. *Trends Immunol* (2013) 34:592–601. doi: 10.1016/j.it.2013.07.002

3. Chiorazzi N, Stevenson FK. Celebrating 20 Years of IGHV Mutation Analysis in CLL. *HemaSphere* (2020) 4:e334. doi: 10.1097/hss.0000000000000334
12. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Iva
16. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: Initial antigen
20. Patten PEM, Ferrer G, Chen S-S, Simone R, Marsilio S, Yan X-J, et al.
19. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R,
18. Lamble AJ, Lind EF. Targeting the immune microenvironment in acute
6. Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes
4. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M,
5. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilleva T,
44. Del Giudice I, Chiaretti S, Tavolaro S, De Propris MS, Maggio R, Mancini F,
41. Lad D, Hoeppli R, Huang Q, Garcia R, Xu L, Toze C, et al. Regulatory T-cells
38. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity.
40. Piper KP, Karanth M, McLarnon A, Kalk E, Khan N, Murray J, et al. Chronic
28. Riches JC, Davies JK, McClanahan F, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. *Blood* (2013) 121:1612–21. doi: 10.1182/blood-2012-09-457531
26. Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. *Clin Cancer Res* (2003) 9:1665–65.
27. Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. *Biochim Biophys Acta - Mol Cell Res* (2016) 1863:471–82. doi: 10.1016/j.bbamcr.2015.11.003
20. Voitl S, Mumm S, Minkert E, Perbellini O, La Rocca F, Ruggieri V, et al. Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. *Clin Cancer Res* (2020). doi: 10.1158/1078-0432.CCR-20-1632
21. Khodadoust MS, Olsson N, Wagar LE, Haahhtaa OAW, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neonatalis. *Nature* (2013) 543:723–7. doi: 10.1038/nature21433
29. Scrivener S, Goddard RV, Kamiński ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. *Leuk Lymphoma* (2003) 44:383–9. doi: 10.1080/104281902100029993
25. Riches JC, Davies JK, McClanahan F, Iqbal S, Agrawal S, et al. T cell activation.
24. Guidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. *Hematology* (2017) 2017:329–37. doi: 10.1182/hedash2017-1.329
22. Richards JC, Davies JK, McClanahan F, Rath R, Iqbal S, Agraval S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. *Blood* (2013) 121:1612–21. doi: 10.1182/blood-2012-09-457531
28. Rovida A, Maccalli C, Scarlò D, Dellabona P, Stamatopoulos K, Ghia P. Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. *Clin Cancer Res* (2020). doi: 10.1158/1078-0432.CCR-20-1632
23. Guidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. *Hematology* (2017) 2017:329–37. doi: 10.1182/hedash2017-1.329
27. Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. *Biochim Biophys Acta - Mol Cell Res* (2016) 1863:471–82. doi: 10.1016/j.bbamcr.2015.11.003
20. Voitl S, Mumm S, Minkert E, Perbellini O, La Rocca F, Ruggieri V, et al. Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. *Clin Cancer Res* (2020). doi: 10.1158/1078-0432.CCR-20-1632
21. Khodadoust MS, Olsson N, Wagar LE, Haahhtaa OAW, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neonatalis. *Nature* (2013) 543:723–7. doi: 10.1038/nature21433
51. Yousef M, Movassaghpoor AA, Shamassanen K, Ghalamfarsa G, Sadreddini S, Jadidi-Niaragh F, et al. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. *Futur Oncol* (2015) 11:567–82. doi: 10.2217/fon.14.2498

52. Hus I, Bojarska-Junak A, Chocholska S, Tomczak W, Wos J, Dmochowska A, et al. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. *PLoS One* (2013) 8:1–8. doi: 10.1371/journal.pone.0078091

53. Jadidi-Niaragh F, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, Sarrafnejad A, et al. Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. *Tumor Biol* (2013) 34:929–40. doi: 10.1007/s13277-012-0628-4

54. Bocko D, Kosmaczewska A, Cizak L, Teodorowska R, Frydecka I. CD28 costimulatory molecule–expression, structure and function. *Arch Immunol Ther Exp (Warsz)* (2010) 58(3):169–77.

55. Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, et al. In Vivo Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia. *J Immunol* (2005) 174:2366–75. doi: 10.4049/jimmunol.174.4.2366

56. Reichardt P, Dornbach B, Gunzer M, APC, T cells, and the immune synapse. *Curr Top Microbiol Immunol* (2010) 340:229–49. doi: 10.1007/978-3-642-03858-7_12

57. Riches J C, Ramsay A G, Gribben J, Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy, *Curr Pharm Des* (2012) 18:3389–98. doi: 10.2174/138161212801227025

58. McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. *Blood* (2015) 126:203–11. doi: 10.1182/blood-2015-01-622936

59. Gorgun G, Ramsay AG, Holderd TAW, Zahrich D, Dieu R, Liu F, et al. Egp–TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. *Proc Natl Acad Sci U S A* (2009) 106:6250–5. doi: 10.1073/pnas.0901166106

60. Palma M, Gentile V, Heimssenn K, Mozaffari F, Nisman-Blaser G, Young E, et al. MLL-SET1I H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. *Haematologica* (2017) 102:562–72. doi: 10.3324/haematol.2016.151100

61. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. *Blood* (2012) 120 (7):1412–21. doi: 10.1182/blood-2012-02-411678

62. Darvin P, Toor SM, Sadibarham Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med* (2018) 50:165. doi: 10.1038/s12276-018-0191-1

63. Hu B, Jacobs R, Ghosh N. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. *Curr Hematol Malig Rep* (2018) 13:543–54. doi: 10.1182/blood-2019-07-807239

64. Ling W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood* (2017) 129:3419–27. doi: 10.1182/blood-2017-02-765685

65. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. *Blood* (2018) 131:68–83. doi: 10.1182/blood-2017-07-740993

66. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. *Lancet Oncol* (2006) 7:480–8. doi: 10.1016/S1470-2045(06)70723-9

67. Carballido E, Veliz M, Komroki J, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. *Cancer Control* (2012) 19(1):54–67. doi: 10.1007/s10512-010-00106

68. Ramsay AG, Evans R, Kaisi S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. *Blood* (2013) 121:2794–14. doi: 10.1182/blood-2012-04-448332

69. Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. *J Clin Invest* (2008) 118(7):2427–37. doi: 10.1172/jci35017

70. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). *Blood* (2013) 121:4137–41. doi: 10.1182/blood-2012-07-470005

71. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med* (2010) 207:2187–94. doi: 10.1084/jem.20100643

72. Blank C, Kuball J, Voellid S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. *Int J Cancer* (2006) 119:317–27. doi: 10.1002/ijc.21775

73. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nat Med* (2016) 22:26–36.

74. Hanna BS, Roessner PM, Scheffold A, Jebaraj BMC, Demerdash Y, Öztürk S, et al. PI3Kδ inhibition modulates regulatory and effector T cell differentiation and function in chronic lymphocytic leukemia. *Leukemia* (2013) 27:134–47. doi: 10.1038/s41375-018-0318-3

75. Norde WJ, Hobo W, Van Der Doort V, Dolstra H. Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention. *Blood* (2012) 120:728–36. doi: 10.1182/blood-2012-02-412510

76. Virgin HW, Wherry EJ, Ahmed R. Redefining Chronic Viral Infection. *Cell* (2009) 138:350–50. doi: 10.1016/j.cell.2009.06.036

77. Wherry EJ. T cell exhaustion. *Nat Immunol* (2011) 12:492–9. doi: 10.1038/ni.2035

78. Zenz T. Exhausting T cells in CLL. *Blood* (2013) 121:1485–6. doi: 10.1182/blood-2013-01-47939

79. Liao Cid L, Hanna BS, Iskar M, Roessner PM, Öztürk S, Lichter P, et al. CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. *Leuk Lymphoma* (2020) 61:351–6. doi: 10.1080/10428194.2019.1660972

80. Shapiro M, Herishanu Y, Ben-Zion-ok, Dezorella N, Sun C, Kay S, et al. Lymphocyte activation gene 3: A novel therapeutic target in chronic lymphocytic leukemia. *Haematologica* (2017) 102:874–82. doi: 10.3324/haematol.2016.149865

81. Vardi A, Stamatoopoulos K, Hadzidimitriou A. T cells in chronic lymphocytic leukemia: Can they fight? *Oncotarget* (2017) 8:99209–10. doi: 10.18632/oncotarget.22277
82. Greaves M. Clonal expansion in B-CLL: Fungal drivers or self-service. J Exp Med (2013) 210:1–3. doi: 10.1084/jem.20122739
83. Os A, Bürgler S, Ribe AP, Funderud A, Wang D, Thompson KM, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep (2013) 4:566–77. doi: 10.1016/j.celrep.2013.07.011
84. Minici C, Gounari M, Ubelhart R, Scarfo L, Dührsen-von Minden M, Schneider D, et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun (2017) 8:15746. doi: 10.1038/ncomms15746
85. Burger IA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 373:2425–37. doi: 10.1056/NEJMoa1509388
86. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood (2014) 123:3390–7. doi: 10.1182/blood-2013-11-535047
87. Wiestner A. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology (2014) 2014:125–34. doi: 10.1183/10282041-20141.1.125
88. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest (1998) 102:1515–25. doi: 10.1172/JCI11899
89. Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Damle RN, et al. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in relapsed/refractory chronic lymphocytic leukemia. J Immunol (2017) 198:1740–7. doi: 10.4049/jimmunol.1601190
90. Rajasagi M, Shulka SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 124:453–62. doi: 10.1182/blood-2014-04-567933
91. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neopeptides in humans. Cancer Immunol Res (2014) 2:228–36. doi: 10.1158/2326-6066.CIR-13-0227
92. Kowalewski D, Stevanovic S, Rammensee HG, Stickel JS. Antileukemia T-cell responses in CLL – We don’t need no aberration. Oncoimmunology (2015) 4:1–3. doi: 10.1080/20019710.2015.1011527
93. Kowalewski D, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A (2015) 112:E116–75. doi: 10.1073/pnas.1416389112
94. Khodadoust MS, Olson N, Chen B, Sworder B, Shree T, Liu CL, et al. B-cell lymphomas present immunoglobulin neoantigens. Blood (2019) 133:887–81. doi: 10.1182/blood-2018-06-845156
95. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol (2002) 3:991–8. doi: 10.1038/ni1102-991
96. Parnam S, Patel K, Pnina-Ibarz J, Ibrutinib (Imbruvica); A novel targeted therapy for chronic lymphocytic leukemia(2014). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103574/ (Accessed August 10, 2020).
97. Mihlbik M, Wiestner A, Sun C. Harnessing the effects of BTKI on T cells for effective immunotherapy against CLL. Int J Mol Sci (2020) 21(1):68. doi: 10.3390/ijms2100068
98. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 122:2539–49. doi: 10.1182/blood-2013-06-507947
99. Okkenhaug K, et al. The PI3K p110δ isoform preferentially inhibits human regulatory T cell function. Oncoimmunology (2014) 3:312. doi: 10.4161/ol.29273.2014
100. Kondo K, Shim H, Thompson PA, Burger JA, Keating M, Estrov Z, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia (2018) 32:960–70. doi: 10.1038/leu.2017.304
101. Sagiv-Barfi I, Kohert HEK, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 112:E966–72. doi: 10.1073/pnas.1500712112
102. Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, et al. Phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv (2018) 2:562–8. doi: 10.1182/bloodadvances.201705263
103. Chellappa S, Kushkehr K, Munthe LA, Tjønnfjord GE, Aandahl EM, Okkenhaug K, et al. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function. J Immunol (2019) 202:1397–405. doi: 10.4049/jimmunol.1701703
104. De Weerdt I, Hofland T, De Boer R, Dobus J, Van Nieuwenhize D, et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv (2019) 3:642–52. doi: 10.1182/bloodadvances.2019003630
105. Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol (2016) 100:888–98. doi: 10.1016/j.critrevonc.2016.02.001
119. Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. *Blood* (2018) 131:1617–21. doi: 10.1182/blood-2017-06-792267

120. Abken H, Koehler P, Schmidt P, Hombach AA, Hallek M. Engineered T cells for the adoptive therapy of b-cell chronic lymphocytic leukaemia. *Adv Hematol* (2012) 2012:595060. doi: 10.1155/2012/595060

121. Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, Van Leeuwen DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. *Mol Ther* (2015) 23:769–78. doi: 10.1038/mt.2015.4

122. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade. *Mol Ther* (2016) 24:1135–49. doi: 10.1038/mt.2016.63

123. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. *Blood* (2012) 119:5697–705. doi: 10.1182/blood-2012-01-403565

124. Giannopoulos K, Wlasiuk P, Dmoszyńska A, Rolinski J, Schmitt M. Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia. *Folia Histochem Cytobiol* (2011) 49:161–7. doi: 10.5603/FHC.2011.0023

125. Van Rooij N, Van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J Clin Oncol* (2013) 31(32):e439–e42. doi: 10.1200/JCO.2012.47.7521

**Conflict of Interest:** KS and AC have received unrestricted grant support from Janssen Pharmaceutica and Abbvie.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021* Vlachonikola, Stamataopoulos and Chatzidimitriou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*